COULD US drug regulators be feeling the heat of government scrutiny? On 13 June, federal health advisers unanimously declined to approve a new weight-loss drug because of concerns that it might cause suicidal thoughts and other psychiatric problems.
In studies presented to a panel of independent experts convened by the Food and Drug Administration (FDA), the drug Acomplia had twice as many psychiatric side effects as a placebo.
“The drug Acomplia had twice as many psychiatric side effects as a placebo”
The US House of Representatives is holding hearings on the reauthorisation of the Prescription Drug User Fee Act (PDUFA)…
